Henderson Backs Two Tech Alternative Trusts

The managers of the Henderson Alternatives Strategies Trust think that biotechnology is perfect for investors who missed out on the technology bull run

David Brenchley 25 September, 2018 | 3:51PM

Healthcare, biotechnology, medicines, drugs, drug pricing, share prices, technology

Biotechnology is just as exciting a sector for investors who either missed out on the technology bull run or are looking for more attractively valued alternatives, according to Janus Henderson’s James de Bunsen and Pete Webster.

Nasdaq continues to power ahead of its domestic, and global, peers, while Apple and Amazon recently became the first corporates to pass the $1 trillion market cap barrier. But there are questions over valuations, despite many bullish on the sector attempting to find new, innovative ways to value these stocks to make them look cheap.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
3i Infrastructure Ord300.39 GBX1.66
Biotech Growth Ord1,296.00 GBX1.89
Henderson Alternative Strategies Trust284.00 GBX2.16
HICL Infrastructure Company Ord174.90 GBX0.52
Polar Capital Global Financials Ord110.04 GBX1.42
Worldwide Healthcare Ord3,656.40 GBX1.01

About Author

David Brenchley

David Brenchley  is a Reporter for Morningstar.co.uk

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies